Cytosorbents Corporation
General ticker "CTSO" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $57.0M (TTM average)
Cytosorbents Corporation does not follow the US Stock Market performance with the rate: -23.9%.
Estimated limits based on current volatility of 3.0%: low 0.69$, high 0.73$
Factors to consider:
- Total employees count: 186 (-6.1%) as of 2023
- Top business risk factors: Liquidity and credit risks, Pandemic risks, Economic downturns and volatility, Manufacturing and commercialization risks, Regulatory and compliance
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.61$, 1.61$]
- 2025-12-31 to 2026-12-31 estimated range: [0.67$, 1.73$]
Financial Metrics affecting the CTSO estimates:
- Positive: with PPE of -2.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -29.69 <= 0.04
- Positive: 19.35 < Shareholder equity ratio, % of 23.45 <= 42.53
- Positive: -4.41 < Investing cash flow per share per price, % of -1.38
- Positive: Interest expense per share per price, % of 2.88 <= 3.31
- Positive: Inventory ratio change, % of -0.78 <= -0.76
Short-term CTSO quotes
Long-term CTSO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $34.69MM | $31.08MM | $35.59MM |
| Operating Expenses | $66.21MM | $63.03MM | $52.38MM |
| Operating Income | $-31.52MM | $-31.95MM | $-16.79MM |
| Non-Operating Income | $-2.38MM | $1.89MM | $-5.62MM |
| Interest Expense | $0.00MM | $0.16MM | $1.40MM |
| R&D Expense | $15.12MM | $15.59MM | $6.92MM |
| Income(Loss) | $-33.91MM | $-30.06MM | $-22.41MM |
| Taxes | $-1.09MM | $-0.81MM | $-1.69MM |
| Profit(Loss)* | $-32.81MM | $-29.99MM | $-20.72MM |
| Stockholders Equity | $35.37MM | $23.28MM | $11.11MM |
| Inventory | $3.46MM | $3.68MM | $2.73MM |
| Assets | $63.23MM | $53.26MM | $47.37MM |
| Operating Cash Flow | $-28.23MM | $-21.66MM | $-14.43MM |
| Capital expenditure | $6.46MM | $0.94MM | $0.28MM |
| Investing Cash Flow | $-6.46MM | $-0.94MM | $-0.67MM |
| Financing Cash Flow | $4.96MM | $14.47MM | $9.33MM |
| Earnings Per Share** | $-0.75 | $-0.67 | $-0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.